EGFR and non-small cell lung carcinoma: conducted another retrospective analysis evaluating concurrent combination of osimertinib plus different chemotherapy regimens in 18 patients with EGFR-mutated NSCLC who were heavily pretreated (median of 3 lines of therapy); 16 of them were T790M positive and all had progressed on single-agent third-generation EGFR-TKI before the addition of chemotherapy.